ketamine research
Articles tagged with “ketamine research”
New Study Finds Ketamine Eases Resistant Bipolar Depression
A new report describes ketamine reducing treatment-resistant bipolar depression symptoms safely. Here is what the evidence shows and what remains unclear.
Ketamine Remission Criteria for Depression Explained
Ketamine remission criteria for depression rely on standardized scales like MADRS and HAM-D. See the score thresholds, evidence quality, and what remission means in practice.
Ketamine's Neuroplasticity Boost Isn't Universal
New research indicates ketamine's neuroplasticity effects vary between individuals, raising questions for low-dose treatment expectations and monitoring.
Foundation Reviews Ketamine Depression Treatment Facts
MedShadow Foundation publishes educational overview of ketamine as antidepressant treatment. What patients need to know about efficacy, safety, and access.
When to Switch or Stay: NMDA Therapy Discontinuation Rates
New analysis reveals why patients stop NMDA receptor antagonist therapy, and what discontinuation data means for low-dose ketamine monitoring and dosing decisions.
Low-Dose Ketamine for Eating Disorders: Anorexia, Bulimia, and Binge Eating
Learn what limited research says about low dose ketamine for anorexia, bulimia, and binge-eating disorder, plus safety and care coordination considerations.
Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons
Review five low-dose ketamine composite case studies, including depression, PTSD, CRPS, bipolar depression, and suicidal ideation, with research-backed clinical lessons.
Ketamine and Benzodiazepines: Clinical Interaction Guide
How benzodiazepines affect ketamine's antidepressant response: GABA vs. glutamate mechanisms, dosing strategies, taper timing, and what the clinical evidence shows.
Ketamine for Depression
Learn what ketamine for depression can and cannot do, how esketamine differs, key safety considerations, and questions to ask a licensed clinician.
Research and Clinical Evidence
A clear review of ketamine and esketamine research for depression, FDA approval, clinical trial limits, safety monitoring, and questions to ask a clinician.
How Fast Does Ketamine Work for Depression?
Low-dose ketamine eases depression symptoms within 1-4 hours, with peak effects at 24-72 hours, compared to 4-6 weeks for SSRIs. See the full timeline.
Does Ketamine Work for Anxiety?
Ketamine may reduce anxiety symptoms for some people, but there is no standard anxiety dose. Review the research, limits, safety questions, and next steps.
Does Ketamine Help with PTSD?
Ketamine for PTSD may reduce symptoms rapidly in some studies, but it is not first-line care. Review research, safety questions, and treatment limits.
Ketamine and Neuroinflammation: How Anti-Inflammatory Effects Support Mental Health
Ketamine lowers inflammatory cytokines and calms microglia, effects that support its antidepressant action alongside biomarker and questionnaire monitoring.
Low-Dose Ketamine for Postpartum Depression
Learn what research says about low-dose ketamine for postpartum depression, including limits of the evidence, breastfeeding questions, monitoring, and treatment discussions.
Cost-Effectiveness of Ketamine Therapy: Health Economic Evidence
Review health economic evidence on IV ketamine and esketamine for treatment-resistant depression, including QALYs, coverage, costs, and questions to ask.
Ketamine in Pregnancy and Lactation: Safety Considerations and Data Gaps
What research shows about ketamine safety in pregnancy and lactation, including preclinical data, placental transfer, breastfeeding guidance, and evidence gaps.
Sex Differences in Ketamine Treatment Response: Hormonal and Genetic Factors
What research says about sex differences in ketamine treatment response, including hormones, genetics, dosing questions, and the limits of current clinical evidence.
Low-Dose Ketamine Infusions for Neuropathic Pain: Evidence and Protocols
Learn what evidence supports low-dose ketamine infusions for neuropathic pain, where benefits are most established, and what monitoring questions to ask.
Glutamate System Modulation by Low-Dose Ketamine
Glutamate system modulation by low-dose ketamine works through NMDA receptor blockade, an AMPA-driven glutamate surge, and BDNF-linked plasticity.
Ketamine-Assisted Psychotherapy: Integrating Pharmacology and Psychotherapy
Learn how ketamine-assisted psychotherapy combines ketamine, preparation, and integration therapy, what the evidence shows, and what to ask a KAP program.
Anti-Inflammatory Properties of Low-Dose Ketamine: Cytokine Modulation
Low-dose ketamine lowers IL-6 and TNF-alpha via NF-kappaB inhibition. See how cytokine modulation shapes its antidepressant and pain effects.
Ketamine-Assisted Therapy for Substance Use Disorders: Clinical Trials Review
A source-backed review of ketamine-assisted therapy for substance use disorders, including early alcohol and cocaine trial findings, safety considerations, and limits of the evidence.
Ketamine Combination Therapy: Augmentation Strategies with Existing Treatments
Learn what current evidence says about ketamine combination therapy with antidepressants, benzodiazepines, mood stabilizers, and psychotherapy.
Low-Dose Ketamine for Social Anxiety Disorder: Preliminary Evidence
Learn what early studies show about low dose ketamine for anxiety and social anxiety disorder, including limits of the evidence, safety considerations, and questions to ask.
Ketamine for OCD: Glutamatergic Modulation of Obsessive-Compulsive Circuits
Ketamine for OCD may offer rapid symptom relief for some people in small studies. Review the evidence, limits, safety considerations, and questions to ask.
Ketamine-Opioid System Interactions: Naltrexone Studies and Debate
How ketamine interacts with opioid receptors, what the naltrexone blockade study found, and what it means for patients on opioid medications.
Ketamine Maintenance Infusion Protocols: Frequency and Duration Optimization
Learn what research supports about ketamine maintenance infusion protocols, including induction, treatment frequency, tapering, duration, monitoring, and relapse planning.
Low-Dose Ketamine for Bipolar Depression: Efficacy and Safety Data
Review the evidence for low-dose ketamine in bipolar depression, including rapid response findings, affective switch concerns, monitoring, and FDA approval limits.
Low-Dose Ketamine for Anxiety Disorders
Learn what research says about low dose ketamine for anxiety, including GAD, social anxiety, OCD, safety monitoring, and questions to ask a clinician.
Ketamine-Assisted Therapy for PTSD and Trauma
Learn what research says about ketamine therapy for PTSD, its limits, safety considerations, and how it may fit with trauma-focused treatment.
Geriatric Considerations in Low-Dose Ketamine Therapy
Learn how low dose ketamine therapy may be considered for older adults, including cardiovascular screening, cognitive concerns, fall prevention, and evidence limits.
Ketamine and the Default Mode Network: Neuroimaging Evidence
How does ketamine affect the brain's default mode network? A review of fMRI, MEG, and PET studies on DMN connectivity, depression, and treatment response.
Low-Dose Ketamine for Chronic Pain Syndromes
Learn when low dose ketamine may be considered for CRPS, neuropathic pain, and fibromyalgia, what research supports, and what to discuss with a pain clinician.
Pharmacokinetics of Ketamine: Absorption, Distribution, Metabolism, and Elimination
Learn how ketamine is absorbed, distributed, metabolized, and eliminated across IV, intranasal, oral, sublingual, IM, and subcutaneous routes.
Defining Sub-Anesthetic Ketamine: Dose Ranges and Therapeutic Windows
Sub-anesthetic ketamine spans 0.1 to 1.0 mg/kg depending on indication. Learn how dose, NMDA receptor occupancy, and route shape each therapeutic window.
Low-Dose Ketamine for Treatment-Resistant Depression
Learn what research says about low dose ketamine for treatment-resistant depression, including rapid effects, safety monitoring, esketamine, and questions to ask a clinician.
Ketamine, Neuroplasticity, and Brain-Derived Neurotrophic Factor
How does low-dose ketamine drive neuroplasticity? A look at BDNF release, TrkB and mTOR activation, and the synapse rebuilding behind its rapid antidepressant effect.
Meta-Analyses of Low-Dose Ketamine for Treatment-Resistant Depression
Meta-analyses of low-dose ketamine for treatment-resistant depression show large 24-hour effects and better durability for racemic ketamine than esketamine.
Rapid-Onset Antidepressant Mechanisms of Low-Dose Ketamine
Low-dose ketamine's rapid-onset antidepressant mechanisms explain why relief begins in hours, not weeks, via NMDA blockade and BDNF-driven synaptic growth.
Patient Selection Criteria for Low-Dose Ketamine Therapy
Learn how clinicians assess candidates for low dose ketamine therapy, including diagnosis, treatment history, safety screening, practical readiness, and monitoring.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.